About immunovant inc - IMVT
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.
IMVT At a Glance
Immunovant, Inc.
1000 Park Forty Plaza
Durham, North Carolina 27713
| Phone | 1-917-410-3120 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -505,606,000.00 | |
| Sector | Health Technology | Employees | 315 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
IMVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.942 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.816 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
IMVT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,605,098.413 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMVT Liquidity
| Current Ratio | 9.086 |
| Quick Ratio | 9.086 |
| Cash Ratio | 8.639 |
IMVT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -58.287 |
| Return on Equity | -64.82 |
| Return on Total Capital | -59.297 |
| Return on Invested Capital | -64.82 |
IMVT Capital Structure
| Total Debt to Total Equity | 0.008 |
| Total Debt to Total Capital | 0.008 |
| Total Debt to Total Assets | 0.008 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |